Graphical Abstract

A structural insight into the P1-S1 binding mode of diaminoethylphosphonic and phosphinic acids, selective inhibitors of alanine aminopeptidases

Ewelina Węglarz-Tomczak, Łukasz Berlicki, Małgorzata Pawełczak, Bogusław Nocek, Andrzej Joachimiak and Artur Mucha

A structural insight into the P1-S1 binding mode of diaminoethylphosphonic and phosphinic acids, selective inhibitors of alanine aminopeptidases

Ewelina Węglarz-Tomczak ^a, Łukasz Berlicki ^a, Małgorzata Pawełczak ^b, Bogusław Nocek ^c, Andrzej Joachimiak ^c and Artur Mucha ^{a,*}

^a Department of Bioorganic Chemistry, Faculty of Chemistry, Wrocław University of Technology, Wybrzeże Wyspiańskiego 27, 50-370 Wrocław, Poland

^b Institute of Chemistry, University of Opole, Oleska 48, 45-052 Opole, Poland

^c Midwest Center for Structural Genomics and Structural Biology Center, Biosciences Division, Argonne National Laboratory, 9700 South Cass Avenue, Argonne, Illinois 60439, USA

* Corresponding author

Fax: +48-71-320-2427. E-mail: artur.mucha@pwr.edu.pl

Keywords: metalloaminopeptidases, aminopeptidase N, *Neisseria meningitidis*, phosphonic and phosphinic acids, APN-inhibitor complex structures, S1 binding mode.

Abstract

N'-substituted 1,2-diaminoethylphosphonic acids and 1,2-diaminoethylphosphinic dipeptides were explored to unveil the structural context of the unexpected selectivity of these inhibitors of M1 alanine aminopeptidases (APNs) versus M17 leucine aminopeptidase (LAP). The diaminophosphonic acids were obtained via aziridines in an improved synthetic procedure that was further expanded for the phosphinic pseudodipeptide system. The inhibitory activity, measured for three M1 and one M17 metalloaminopeptidases of different sources (bacterial, human and porcine), revealed several potent compounds (e.g., $K_i = 65$ nM of **1u** for HsAPN). Two structures of an M1 representative (APN from *Neisseria meningitidis*) in complex with *N*-benzyl-1,2-diaminoethylphosphonic acid and *N*-cyclohexyl-1,2-diaminoethylphosphonic acid were determined by the X-ray crystallography. The analysis of these structures and the models of the phosphonic acid complexes of the human ortholog provided an insight into the

role of the additional amino group and the hydrophobic substituents of the ligands within the S1 active site region.

Introduction

A detailed substrate fingerprint study [1] has recently revealed a broad substrate tolerance of the S1 pocket of the M1 alanine metalloaminopeptidase from *Neisseria meningitidis* (NmAPN) – a gram-negative diplococcus bacterium that is considered the major causative agent of meningitis and other meningococcal diseases [2-4]. Fluorogenic substrates, derived from unnatural α -amino acids that comprise bulky hydrophobic P1 side-chain residues bearing a fragment of a basic character, were ranked among the most favored ligands. A similar hydrophobic and base-oriented P1 specificity profile was observed for mammalian (human and porcine) [5] and protozoan (*Plasmodium falciparum* [6] and *Eimeria tenella* [7]) alanine aminopeptidases, the abundantly spread metallohydrolases of multiple functions and medical implications [8-10]. The privileged features of the amino acid substrates can be readily translated into the structure of potential inhibitors. The α -aminoalkylphosphonic acids provide an opportunity to install the preferred P1 substituents on the N-C-P scaffold and are commonly recognized as transition state analogue inhibitors of zinc metalloaminopeptidases [11]. However, the insertion of an additional heteroatom-based group into the substituent structure is a separate and not trivial task, in particular to be performed in a parallel manner. One such convenient modification is aziridinephosphonate ring opening to yield N'-substituted 1,2-diaminoethylphosphonic acids, which was originally proposed to provide inhibitors of metalloaminopeptidases from the porcine kidney [12]. The compounds contain an extra β -amino group that modifies the character of the P1 substituent to basic. Indeed, several compounds were found to be good inhibitors of mono-zinc alanyl aminopeptidase and discriminate versus two zinc atom-containing leucine aminopeptidase (LAP), for which they exhibited poor or no inhibition [12]. This was a quite unique observation, as the structural fragment $\text{H}_2\text{N-C-PO}_2$ typically provides much more effective complexation systems for the two zinc ions in LAP than for the single one in APNs [11,13]. Apparently, the additional β -amino group does not allow convenient P1-S1 side-chain docking (hydrophobic residues are strongly preferred) and distorts the overall binding mode to this particular aminopeptidase. The precise reasons for the good affinity to the porcine APN remain elusive. For NmAPN, we recently postulated that an additional heteroatom group located in the proximity of the side chain is able to enhance interactions with the glutamate-rich anionic site that is formed by Glu117, Glu260 and Glu316 and typically dedicated to the binding the N-terminus of peptidic substrates (Fig. 1, panel A) [1].

Figure 1. Structure of N'-substituted 1,2-diaminoethylphosphonic acids (**1**) and 1,2-diaminoethylphosphinic pseudodipeptides (**2**) and the presumed role of the amino groups in binding to *Nm*APN.

As N'-substituted 1,2-diaminoethylphosphonic acids (**1**) are also promising lead compounds to obtain specific and potent inhibitors of alanyl aminopeptidase by the P1' elongation to phosphinic dipeptides (**2**, Fig. 1, panel **B**), we have decided to revisit the issue. An extensive series of novel compounds was obtained in an improved synthetic approach. Their inhibitory activity was tested towards four enzymes: *Nm*APN, human (*Hs*APN) and porcine APN (*Ss*APN), and LAP. Finally, the crystal structures of two inhibitor complexes (*Nm*APN-**1h**, and *Nm*APN-**1n**) were determined by X-ray crystallography and compared against modeled *Nm*APN-inhibitor and *Hs*APN-inhibitor complexes, providing structural insight of the ligand-protein interactions and inhibition modes. The potential of the P1' extension was evaluated for selected N' substituents.

Results and discussion

Synthesis of 1,2-diaminoethylphosphonic acids

The α,β -unsaturated system of dialkyl vinylphosphonates **3** (Scheme 1) is the usual substrate for the synthesis of 1,2-diaminoethyl derivatives **1** in a pathway via aziridinephosphonates. In the classical Gabriel-Cromwell method, bromine is readily added to the unsaturated bond to produce 1,2-dibromophosphonate esters **4** [14]. Then, consecutive eliminations of HBr with gaseous and liquid ammonia yield the heterocyclic system **5** in the historical literature method (Scheme 1, pathway **A**) [14]. Nucleophilic substitution with a primary or secondary amine enables the aziridine ring opening [15]. However, the approach is characterized by at least two shortcomings. First, ammonia is the reagent of choice to obtain the non-substituted

aziridine, but the elimination is capricious and not pure [14,16]. Second, for not fully clear reasons, esters of aziridinephosphonate **5** are very resistant to the nucleophilic attack of an amine and ring opening. As a consequence, they demand hydrolysis to free acids **6** prior to substitution [15,16]. These complications were associated with problematic purification, as a careful ion-exchange chromatography was applied after each of those steps.

R^1 = H (**1a**), Me (**1b**), *n*-Pr (**1c**), *i*-Bu (**1d**), *n*-Hex (**1e**), $\text{NH}_2\text{-(CH}_2\text{)}_2$ (**1f**), $\text{NMe}_2\text{-(CH}_2\text{)}_2$ (**1g**), *c*-Hex (**1h**), *c*-heptyl (**1i**), 2- NH_2 -*c*-Hex (**1j**), tetrahydrofuran-2-ylmethyl (**1k**), piperidin-4-ylmethyl (**1l**), 2-(piperazin-1-yl)ethyl (**1m**), Bzl (**1n**), α -Me-Bzl (**1o**), 4-*t*-Bu-Bzl (**1p**), 2-Ph-ethyl (**1q**), 4- NH_2 -Bzl (**1r**), 4-OMe-Bzl (**1s**), 4- NH_2CH_2 -Bzl (**1t**), 2-(4-OMe-Ph)ethyl (**1u**); R^2 = H
 R^1, R^2 = $\text{-(CH}_2\text{)}_5\text{-}$ (**1v**), $\text{-(CH}_2\text{)}_2\text{O(CH}_2\text{)}_2\text{-}$ (**1w**)

Scheme 1. Reagents and conditions: a) Br_2 , CH_2Cl_2 ; b) gaseous NH_3 then liquid NH_3 (or $\text{NH}_3/\text{H}_2\text{O}$ followed by $\text{NaOH}/\text{H}_2\text{O}$); c) $\text{HCl}/\text{H}_2\text{O}$; d) $\text{R}^1(\text{R}^2)\text{NH}$, EtOH; e) TsNH_2 , PhI=O , CuCl , MS 4 Å, $\text{MeCN}/\text{MeNO}_2$ (4:1, vv); f) BzI-NH_2 ; g) Et_3N then Ph(R)CHNH_2 ; h) H_2 , 10% Pd/C , MeOH; i) $\text{R}^1(\text{R}^2)\text{NH}$, $\text{H}_2\text{O}/\text{dioxan}$; j) $\text{H}^+/\text{RP-HPLC}$. For the expanded structures of R^1 and R^2 , see Table 1.

N-Tosylaziridines are considered much more susceptible to nucleophilic substitution than their non-modified counterparts. Accordingly, our first alternative approach involved the verification of *N*-tosylaziridinephosphonates **7** as convenient intermediates (Scheme 1,

pathway **B**). Indeed, we managed to open a tosylated phosphonate diester with benzylamine in a simple and clean manner. However, obtaining such a material (**7**) by nitrene-mediated aziridination appears to be far more problematic. Contrary to the literature data, different versions of both metal and non-metal assisted oxidative additions of Chloramine T (*N*-chlorotosylamide sodium salt) to the double bond of **3** are ineffective [17-19]. Extensive optimization of the reaction conditions with other tosyl precursors and hypervalent iodobenzene-based reagents [20-22] finally led to the desired products under copper(I) catalysis [21], but in a very poor yield (< 10% after column chromatography). Although the subsequent substitution to compounds **8** looked promising, we decided to abandon the approach.

In such circumstances, the elimination option was reconsidered, but ammonia was replaced by Et₃N (the first stage) and subsequently by a benzylamine derivative (the second step) [23]. The use of benzyl or α -methylbenzylamine gave *N*-substituted aziridinephosphones **9** in a reasonable yield (Scheme 1, pathway **C**). The benzylamine derivatives were chosen as they could be readily hydrogenated to free aziridine **5**. Diphenylmethylaniline (benzhydrylamine) did not work to the same extent, apparently because of the decreased nucleophilicity and steric hindrance of the amino group. Products **9** were easily purified by flash chromatography on silica. The subsequent catalytic hydrogenation was performed in standard conditions prior to the ring opening with selected amines. The two-step procedure appeared more practical to obtain **5** than the direct use of ammonia.

An excess of the reacting amine, harsh reaction conditions and the use of a water medium in place of an organic solvent ensured the substitution without the prerequisite hydrolysis of the ester groups. As a matter of fact, both transformations proceeded simultaneously, and the 1,2-diaminoethylphosphonate products were in the form of ammonium salts of phosphonate monoesters **10** and preparatively separated after HPLC chromatography to afford **11**. Apparently, the monohydrolysis occurring in basic aqueous conditions sufficiently increased the susceptibility of the aziridine to substitution for it to be opened without requiring exhaustive hydrolysis. Different primary and secondary structurally diversified (linear, branched, cyclic and benzyl, including heteroatom-substituted, listed in Scheme 1 and Table 1) amines reacted readily. In the cases of difunctional amines, the high excess of the nucleophilic component ensured mono-substitution, including evident regioselectivity. For example, the aromatic amino function of 4-aminobenzylamine remained non-modified, as evidenced in products **11r**.

Acidic conditions, applied to remove the remaining alkyl ester group, completed the reaction sequence. Hydrogenation, ring opening/monohydrolysis and the final hydrolysis could be also performed in a convenient one-pot manner. Each step proceeded efficiently and can be easily controlled by ^{31}P NMR, so that the removal of solvents is the only operation demanded before the following stage. The separation of the target compounds **1** involves standard treatment with propylene oxide. Analytical samples could be conveniently recrystallized from water. In summary, even though the overall procedure is extended by one step, it seems to be advantageous to the approach described previously. The detailed synthetic procedure together with the spectroscopic and analytical data for novel compounds is given in the Supporting Materials.

SAR studies and binding modes of 1,2-diaminoethylphosphonic acids

Amines of a different structure were used to explore the efficiency of binding of the N' substituent of 1,2-diaminoethylphosphonic acids to the NmAPN and the reference aminopeptidases (Table 1). The collection included the unsubstituted compound **1a**, being the product of the reaction of aziridine with ammonia, alkyl (**1b-e**), cycloalkyl (**1h** and **1i**) and phenylalkyl derivatives (**1n-q**). The three series of compounds were further diversified with representatives containing an additional functionalization: **1f** and **1g** for alkyls, **1j-m** for cycloalkyls and **1r-u** for arylalkyls. The functionalization mainly involved an extra terminal amino group or an ether function, which were dedicated to forming interactions with the distal part lining the S1 binding region of NmAPN. Finally, piperazine (**1v**) and morpholine analogues (**1w**) were derived from cyclic secondary amines.

The studied compounds were found to be good, generally low-micromolar-range competitive and fast-binding inhibitors of NmAPN. Unsubstituted 1,2-diaminoethylphosphonic acids (**1a**) appeared to be the most potent inhibitor, with a submicromolar K_i value (0.6 μM). The binding mode of **1a** with NmAPN obtained by molecular modeling (Fig. S1) principally confirmed the assumed interactions of the amino groups with the active site glutamate residues. Despite unfavorable electrostatic repulsions both positively charged nitrogen atoms are aimed at Glu117 and Glu260 (compare also Fig. 1, panel A). Compounds derived with bulky, extended alkyl, cycloalkyl and arylalkyl fragments (**1e**, **1h**, **1i**, **1p** and **1q**) were only slightly less potent ($K_i = 1.1\text{-}3.0\ \mu\text{M}$). The presence of a smaller alkyl chain (**1b-d**), a heterocyclic ring (**k-m**), a benzyl portion (**1n** and **1o**) and cyclic piperazine or morpholine (**1v** and **1w**) diminished the activity, typically by 1-2 orders of magnitude. Interestingly, an additional terminal amino or methoxy group located at the benzyl residue (compounds **1r** and

1s) improved the affinity by 3-to-4-fold compared with the non-modified analogue **1n** (4.2 and 4.8 μM versus 16.6 μM). A similar effect was achieved for a more flexible and basic 4-aminomethyl functionalization of benzylic R^1 (**1t**, $K_i = 4.2 \mu\text{M}$). Twice as potent as the heteroatom-modified benzyls was the elongated 4-methoxy-functionalized phenylethyl fragment of compound **1u** ($K_i = 2.3 \mu\text{M}$).

Table 1. Structure-activity relationship for 1,2-diaminoethylphosphonic acid inhibitors of *N. meningitidis* APN and mammalian aminopeptidases: porcine and human APNs and porcine LAP (NI – no inhibition up to 0.8 mM inhibitor concentration). In the cases of compounds previously tested toward *Ss*APN and LAP [12] the originally measured activity is presented, unless the difference exceeds 25%.

No.			K_i [μM]			
	R^1	R^2	<i>Nm</i> APN	<i>Ss</i> APN	<i>Hs</i> APN	LAP
1a	H	H	0.589 ± 0.17	2.88 ± 0.43 (19.0 [12])	10.6 ± 2.2	NI [12]
1b	Me	H	29.6 ± 4.4	46.0 [12]	7.42 ± 0.96	NI [12]
1c		H	6.72 ± 1.1	1.91 [12]	1.66 ± 0.13	NI [12]
1d		H	23.3 ± 0.6	1.71 [12]	2.51 ± 0.29	NI [12]
1e		H	1.11 ± 0.11	1.21 ± 0.22	0.297 ± 0.093	119 ± 14
1f		H	43.1 ± 5.4	32.4 ± 3.9	41.1 ± 2.5	289 ± 23
1g		H	26.0 ± 1.4	19.3 ± 0.46	5.74 ± 0.26	72.6 ± 6.0

1h		H	2.38 ± 0.28	$0.87 [12]$	0.691 ± 0.046	NI [12]
1i		H	1.68 ± 0.03	0.520 ± 0.040	0.397 ± 0.077	20.8 ± 2.7
1j		H	26.5 ± 3.7	27.7 ± 1.6	13.5 ± 0.70	240 ± 8.6
1k		H	9.67 ± 0.49	3.64 ± 0.38	0.782 ± 0.015	69.1 ± 6.8
1l		H	11.4 ± 1.7	9.39 ± 0.80	3.29 ± 0.52	68.4 ± 6.8
1m		H	27.7 ± 0.46	7.00 ± 0.89	3.22 ± 0.15	55.8 ± 7.6
1n		H	16.6 ± 0.71	$2.30 [12]$	0.341 ± 0.091	350 [12]
1o		H	15.4 ± 0.97	14.5 ± 2.4 ($2.80 [12]$)	0.391 ± 0.11	600 [12]
1p		H	1.42 ± 0.050	6.58 ± 0.25	2.55 ± 0.37	71.1 ± 1.2
1q		H	3.00 ± 0.035	6.04 ± 0.81	1.22 ± 0.18	108 ± 7.8
1r		H	4.79 ± 0.18	2.49 ± 0.057	1.49 ± 0.19	7.02 ± 0.42

1s		H	4.32 ± 0.52	2.29 ± 0.046	0.357 ± 0.036	26.2 ± 2.0
1t		H	4.19 ± 1.2	5.42 ± 0.28	2.89 ± 0.43	26.5 ± 2.1
1u		H	2.33 ± 0.14	0.723 ± 0.040	0.065 ± 0.009	19.5 ± 2.4
1v			12.5 ± 2.1	$14.7 [12]$	6.04 ± 0.38	$1410 [12]$
1w			197 ± 8.9	94.2 ± 11	37.7 ± 1.6	NI

The actual binding mode of selected 1,2-diaminoalkylphosphonic acids to the active site of *Nm*APN was revealed by crystallographic studies (Fig. 2, panel **A** for *N'*-cyclohexyl and panel **B** for *N'*-benzyl derivative). The crystals of the recombinant enzyme soaked with an inhibitor do not show significant changes in the overall binding site architecture compared with the ligand-unbound protein [24], nor to those visualized for *Nm*APN complexed with 1-aminoalkylphosphonic acids [25]. Two negatively charged phosphonic oxygen atoms coordinate the catalytic zinc ion (2.41 and 2.23 Å for **1h** and 2.07 and 2.20 Å for **1n**), mimicking the *gem*-diolate transition state of the scissile peptide bond. One of them also interacts with the hydroxyl group of Tyr377 (2.55 Å for **1h** and 2.52 Å for **1n**), the key residue for the hydrolytic mechanism. Nevertheless, the phosphonate of 1,2-diaminophosphonic acids seems to be buried somewhat shallower than in the 1-amino analogues for which the corresponding distances are slightly shorter, typically, O-Zn below 2.1 Å and O-Tyr377 below 2.5 Å [25]. The fundamental contacts (the salt bridges) of the α -amino group with the glutamates responsible for the binding of the N-terminus are also well reproduced, in particular for the *N'*-benzyl derivative **1n**, with distances 2.65 Å to Glu117 and Glu260. In general, the NCP fragment of compounds **1** binds to the *Nm*APN in a fairly predictable way with some minor distortions, apparently caused by the bulkiness of the *N'* substituent.

A

B

Figure 2. Close-up views showing interactions of *N'*-cyclohexyl- (**1h**, panel **A**) and *N'*-benzyl-1,2-diaminoalkylphosphonic acid (**1n**, panel **B**) ligands with NmAPN as observed in the crystal structures. The hydrogen bonds and ligand-metal interactions are marked as green lines, distances are shown in Angstroms.

Large-size P1 residues fill the hydrophobic S1 cleft well. To our surprise, the β -amino group is indiscriminately positioned and plays a variable role in binding. For the *N'*-cyclohexyl residue of **1h**, it is aimed at the interior of the pocket, and its hydrogen-bonding potential is somewhat shielded by the intramolecular alkyl and cycloalkyl surroundings. Nevertheless, it is directed straight to the negatively charged surface (compare also Fig. S1), although beyond the hydrogen bond distance (3.43 Å to carboxylate oxygen atom of Glu117). For the *N'*-benzyl, the β -amino functionality is located in the opposite conformation. It is also at the limit of the interatomic distances of hydrogen bonding to C=O of Ala258 and to the third, solvent-exposed, phosphonate oxygen atom (both distances 3.14 Å). Most probably these plausible interactions are not essential effects, as 1-amino-3-phenylpropylphosphonic acid (the homophenylalanine analogue), the compound missing the β -amino group, is bound in a quite similar manner (Fig. S2) but exhibits an improved activity ($K_i = 1.26 \mu\text{M}$ [1]).

The range of inhibition obtained for porcine kidney SsAPN is quite similar to that measured for the *N. meningitidis* ortholog. In Table 1, the results obtained for novel compounds **1e**, **1g**, **1j-l** and **1n** are compiled with the data acquired previously (if currently measured K_i values are consistent with the literature data for compounds **1a-d**, **1f**, **1h**, **1i** and **1m** [12] and do not differ by more than 25%, the original number is given; otherwise, both are included). For SsAPN, a much broader tolerance to different substitutions is visible. The majority of the studied inhibitors show a dissociation constant below 10 μ M, with the newly synthesized cycloheptyl derivative **1g** being the most potent ($K_i = 0.5 \mu$ M).

Far more impressive data in terms of the inhibition constant value were collected for human alanine aminopeptidase. Several aliphatic compounds display K_i below 1 μ M, being equally (*N'*-*n*-propyl, **1c**, *N'*-cyclohexyl, **1h**, and *N'*-cycloheptyl, **1i**) or more active (*N'*-*n*-hexyl, **1e**, $K_i = 0.3 \mu$ M) than for the highly homologous porcine APN. Significantly, arylalkyl residues are much better accepted for human than for pig APN. *N'*-Benzyl, **1n**, *N'*-(α -methylbenzyl), **1o**, and *N'*-(4-methoxybenzyl), **1s**, displayed strong inhibition, with K_i values falling in a submicromolar range (all values below 0.4 μ M). The higher homolog of the last compound (*N'*-2-(4-methoxyphenyl)ethyl, **1u**) appeared to be the most potent compound found in this study ($K_i = 65$ nM). To the best of our knowledge, it is the most active amino acid analogue inhibitor of HsAPN reported to date. To discuss the presumed binding mode and the reasons for the potency of selected compounds, molecular modeling studies were performed. The crystal structure of alanyl aminopeptidase from *H. sapiens* [26] was used to dock the ligand and analyze the interactions. The HsAPN-**1u** complex (Fig. 3) shows a typical pattern of contacts of the ligand N-C-P fragment with the enzyme, similar to those described above for NmAPN, namely, the involvement of two P-O oxygen atoms in Zn complexation and the ion pairing / hydrogen bonding of the α -amino with glutamates / glutamine (Glu355, Glu414 and Gln213). Interestingly, the β -amino group adopts a conformation similar to that evidenced in the crystal structure of the *N'*-benzyl-1,2-diaminoalkylphosphonic acid-NmAPN complex. The group is exposed externally out of the S1 enzyme cavity and tentatively linked with the solvent-aimed oxygen atom *via* an intramolecular hydrogen bond. The (4-methoxyphenyl)ethyl fragment fits particularly well to the S1 binding site, filling it very tightly (Fig. 3 and Graphical Abstract). The aromatic ring is surrounded by the phenyl of Phe348 (edge to face) and the amide groups of Gln211 and Asn350. The electron-rich character of the aromatic ring definitely improves the contacts with the neighboring residues. The ether oxygen atom is in proximity to the N-terminal amide N-H of Asn350, but the

potential hydrogen bonding can be a vague suggestion because of a not favored geometry. Suggestion of the interaction between the inhibitor oxygen atom of OMe and the side-chain amide NH₂ group of Asn350 seems to be more justified for compound **1s**, a methylene group shorter homologue of **1u**. The high activity of inhibitor **1s** ($K_i = 357$ nM) can be attributed to this specific bond (Fig. S3) as the overall P1-S1 fit is not so perfectly tight as modeled for **1u**. The latter statement is also valid for the *N'*-2-phenylethyl substituent of **1q**, lacking OMe group compared to **1u** (Fig. S4), which gives rise to a moderate inhibitory potency. To conclude, the length and character of the *N'*-2-(4-methoxyphenyl)ethyl portion can be considered optimal to bind to the S1 pocket of *Hs*APN.

Figure 3. A model of the complex of *N'*-[2-(4-methoxyphenyl)ethyl]-1,2-diaminoalkylphosphonic acid (**1u**) with *Hs*APN showing P1-S1 interactions. Intra- and intermolecular hydrogen bonds and ligand-metal interactions are marked in green.

Discussing the selectivity issues between APNs from different sources, several interesting discrimination cases can be observed. For example, unsubstituted derivative **1a** clearly favors binding to *Nm*APN. The difference in inhibition constants is approximately 5-fold to porcine

and 20-fold to human enzyme. The opposite cases (mammalian APNs *versus* the bacterial one) are even more pronounced. For example, compound **1d** (*N'*-isopropyl) exhibits over an order of magnitude higher potency in favor of *Ss*APN and *Hs*APN than *Nm*APN. Certain inhibitors preferentially bind to only the human ortholog. The *N'*- α -methylbenzyl (**1o**) derivative distinguishes human aminopeptidase, with $K_i = 0.4 \mu\text{M}$ *versus* $K_i = 15 \mu\text{M}$ for the other two APNs. The much more potent *N'*-[2-(4-methoxyphenyl)ethyl]-1,2-diaminoalkylphosphonic acid (**1u**) is also at least 10-fold more active for *Hs*APN than for the alanyl aminopeptidase of other organisms.

The selectivity ratio between the APNs and LAP is indeed significant. In general, *N'*-alkyl- and *N'*-cycloalkyldiaminoethylphosphonic acids do not inhibit (up to 800 μM inhibitor concentration) or poorly inhibit porcine kidney leucine aminopeptidase, whereas they appear to be quite active for APNs ($K_i \sim 1 \mu\text{M}$). The cyclohexyl derivative **1h** is the most significant example. It is a low micromolar inhibitor of three alanyl aminopeptidases and does not influence the LAP activity at all. In this and similar instances, the selectivity ratio can be estimated to be three orders of magnitude. When the effect of LAP inhibition is measurable, the ratio is typically 1.5-2 orders of magnitude (compare, for example, the K_i values found for compound **1e**: 1.1 μM for *Nm*APN, 1.2 μM for *Ss*APN and 0.3 μM for *Hs*APN *versus* 119 μM for LAP). Only individual compounds (arylalkyl) show somewhat significant affinity toward LAP. Among them, the *N'*-4-aminobenzyl analogue (**1k**) can be considered a universal inhibitor of aminopeptidases, with all the K_i values between 2.5 and 7.0 μM .

Synthesis and activity of 1,2-diaminoethylphosphinic-derived dipeptides

In continuation, we undertook an effort to adapt the optimized protocols of obtaining and opening the corresponding aziridine system for a suitable phosphinic dipeptide precursor. Such a building block should contain an appropriate P1' fragment. The aromatic ring of the benzyl-derived portion is favorably bound in a shallow and hydrophobic S1' cleft [27], so we selected unsaturated compound **16** and aziridine **18** (Scheme 2) as the target scaffolds. The synthetic challenge to prepare vinylphosphinate **16** involves a multistep approach starting from methyl α -benzylacrylate **12** [28,29]. Diethyl phosphite was readily added to the acrylate in a phospho-Michael reaction under strong base catalysis [30] to obtain **13**. The triester was selectively monodealkylated with NaI in acetone [31] to the mixed diester **14**. Subsequently, the phosphonic monoacid function was converted into the corresponding chloridate **15** by thionyl chloride [32]. Without preparative separation, phosphonochloridate was reacted with

vinylmagnesium chloride [33], the Grignard compound, to form the demanded vinyl-to-phosphorus portion. The following steps of the procedure were analogous to those elaborated for the amino acid analogs. They involved the addition of bromine to yield **17** and ring closure to aziridine **18**. The last compound was heated in parallel with selected amines (or ammonia) to obtain the N'-substituted diaminoethyl fragment of **19**. Catalytic hydrogenation and a final hydrolysis led to the target products **2**.

Scheme 2. Reagents and conditions: a) *t*-BuOK, HP(O)(OEt)₂, MeOH; b) NaI, acetone; c) SOCl₂, CH₂Cl₂; d) CH₂=CHMgCl, CH₂Cl₂; e) Br₂, CH₂Cl₂; f) Et₃N then Ph(R)CHNH₂; g) R¹NH₂, H₂O/dioxan; h) H₂, 10% Pd/C, MeOH; i) HCl/H₂O.

As evidenced by previous studies on organophosphorus inhibitors, more potent inhibitors of aminopeptidases are those extended to the P1' fragment rather than simple amino acid analogues designed to bind only within the S1 region [11,25,27,34]. This is not the case in the current study. The phosphinic dipeptides **2**, although containing selected favorable N'-substituents, appeared to be less potent inhibitors of alanyl aminopeptidases than the corresponding phosphonic amino acids **1** (Table 2). A particular drop in activity was

evidenced for *Nm*APN. The K_i values increased by 1-2 orders of magnitude and exceeded 100 μM for the majority of compounds. A minor loss of activity was evidenced for the porcine APN, typically a 2-5-fold decrease. For the human enzyme, the results obtained for dipeptides are comparable with those acquired for the amino acid analogues. *N'*-Alkyl and cycloalkyl derivatives **2b-e** showed good affinity, with K_i values between 0.2 and 1.1 μM (the bulkier the better). Each of these results was slightly improved when compared with corresponding compounds **1c**, **1d**, **1i** and **1j** comprising only the P1 substituent ($K_i = 0.4\text{-}2.5$ μM). The affinity of the most potent amino acid compound **1u** did not change (within the experimental error) upon the structure elongation and remained at a very good nanomolar level for **2f**.

Table 2. Structure-activity relationship for 1,2-diaminoethylphosphinic dipeptide inhibitors of *N. meningitidis* APN and mammalian aminopeptidases.

No.		K_i [μM]			
		<i>Nm</i> APN	<i>Ss</i> APN	<i>Hs</i> APN	LAP
2a	$R^1 = \text{H}$	171 ± 5.5	29.0 ± 2.3	4.45 ± 0.50	64.4 ± 2.6
2b	$R^1 =$	131 ± 16	6.74 ± 0.54	1.11 ± 0.057	21.0 ± 2.5
2c	$R^1 =$	101 ± 13	4.54 ± 0.26	0.499 ± 0.031	15.2 ± 2.6
2d	$R^1 =$	114 ± 14	3.83 ± 0.43	0.275 ± 0.040	28.3 ± 2.5
2e	$R^1 =$	109 ± 13	3.24 ± 0.41	0.207 ± 0.019	23.8 ± 2.4
2f	$R^1 =$	39.5 ± 9.6	1.48 ± 0.18	0.078 ± 0.009	21.1 ± 2.6

The affinity of pseudodipeptidic compounds **2** towards LAP flattened. Those amino acids that exhibited a moderate potency ($K_i \sim 20 \mu\text{M}$, **1i** and **1u**) retained the activity upon the structure elongation (**2e** and **2f**, respectively). Those that were inactive (**1c**, **1d** and **1h**) gained affinity after the P1' addition (**2b-d**) to the aforementioned level. Only the N'-unsubstituted derivative **2a** displayed three-fold worse inhibition parameters than the other dipeptides. This improvement is definitely associated with benzyl incorporation, a favorable residue accommodated in the S1' binding sub-site. Participation of the P1' part of the molecules in interactions with LAP seems to be decisive in determining the compound activity, which does not depend on the P1 portion structure.

Discussion and conclusions

A careful and thorough optimization of the P1 and P1' substituent structure (modification/extension) in phosphorus-based transition state inhibitors and the examination of their interactions with the corresponding sub-sites has led to the discovery of very potent and selective inhibitors of metallo-dependent aminopeptidases, including APNs [25,27,34]. Although synthetically challenging, this method seems to be a rational and attractive approach for the construction of new ligands and an alternative to the elongation of pseudopeptidic sequences [35]. The selectivity issues are not trivial aspects, as the amino acid content and architecture of the APN active sites are well conserved between species. Nevertheless, certain structural nuances can be explored by systematic guest-host matching, which in turn demands access to extensive libraries of compounds. The parallel opening of aziridine phosphonates/phosphinates with amines fulfills these requirements. We have presented here an improved and versatile version of the reaction, validated for both amino acid and dipeptide analogues. It enables the preparation of a vast collection of diaminoethyl compounds, substituted at the β -amino group. The substitution is defined by the structure of the amine substrates, which include alkyls, cycloalkyls and arylalkyls, also variously modified. Very potent inhibitors were identified among the N'-derived 1,2-diaminoethylphosphonic acids, and what is equally important, the compounds showed satisfactory selectivity. In particular, the studied bacterial ortholog, *Nm*APN, could be exclusively inhibited by the non-substituted compound **1a**. N'-Arylalkyls (e.g., α -methylbenzyl in compound **1o**) are specific residues that give rise to K_i constants at least one order of magnitude lower for human APN than for the remaining two enzymes. One member of this group (N'-[2-(4-methoxyphenyl)ethyl]-substituted phosphonic acid **1u**) appeared to be the most potent inhibitor revealed in the study

($K_i = 65$ nM). N'-substitution with an extended alkyl and cycloalkyl (e.g., **1e** and **1i**) produced universal ligands with good affinity to all three bacterial and mammalian APNs. Less bulky derivatives (**1c**, **1d** and **1h**) of an aliphatic character retain their activity towards APNs and do not inhibit LAP at all, even though both aminopeptidases show a quite similar substrate specificity [36,37]. The SAR results of analogous compounds, alkyl and cycloalkyl-substituted α -aminophosphonic acids (missing the β -amino group), are mirror-reflected: they display a low micromolar and submicromolar inhibition of LAP and poor inhibition of APN (porcine kidney) (Fig. 4) [12,38].

Figure 4. Preference of the P1 substituents in aminophosphonic acid inhibitors of neutral aminopeptidases, a heteroatom-modified cycloalkyl of **1h** favored by APNs and a typically lipophilic cycloalkyl favored by LAP [12,38].

Accordingly, the motivation of our study on diaminoethylphosphonic/phosphinic compounds was also focused on addressing the basic question of the structural reasons for such an unusual behavior. The crystal structures of a few ligands complexed with *Nm*APN did not provide a definite answer on the role of the β -amino group in binding. Instead, two possible conformations were envisaged (Fig. 2 and S1). For the *N'*-cyclohexyl derivative **1h** (Fig. 2A), the β -amino group is buried in the S1 pocket without any close contacts, yet it is clearly pointed at the negatively polarized glutamate region, in particular at Glu117. This is in general accordance with our hypothesis depicted in Fig. 1A, confirmed by molecular modelling for unsubstituted analogue **1a** (Fig. S1), and interactions displayed by certain disubstituted ligands, including diaminocarboxylic compounds complexed with *Escherichia coli* APN [39].

In the structure of *N'*-benzyl compound **1n** (Fig. 2B), the β -amino group is exposed outside of the S1 cavity of *Nm*APN. In this case, the ligand conformation is the most likely to be stabilized by an intramolecular interaction with the phosphonic acid and a hydrogen bond with a neighboring residue (Ala258). Similar arrangements could be observed in three

modeled inhibitor-*Hs*APN complexes (Fig. 3, S3, and S4). These interactions might produce a certain energetic gain upon complexation. However, taking into account the number of hydrogen bonds with water that need to be released upon the inhibitor entry to the active site, the formation of new weak contacts is only moderately profitable.

The lack of potency of diaminoalkylphosphonates towards LAP is easier to explain. The overall binding mode of the N-C-P ligands to the two-zinc containing aminopeptidase is quite different. LAP does not contain such a precisely defined acidic region. Instead, Asp273 and one of the metal ions are involved in the binding of the N-terminal amino group. This is the supplementary role of the zinc apart from participation in the complexation of the gem-diolate transition state product of the scissile bond hydrolysis. This was confirmed by the crystal structure of transition state inhibitor, the phosphonic analogues of leucine bound to this aminopeptidase [40]. An additional β -amino functionality would definitely alter the favorable and fragile interaction network.

The decrease in potency, in particular towards *Nm*APN, observed for phosphinic dipeptides **2** upon extension of the diaminoethylphosphonate structure **1** by the P1' fragment seems to be the most unexpected result revealed in this study. Typically, tightening organophosphorus ligand-APN interactions by P1'-S1' contacts provides at least a one to two order of magnitude gain in the binding constants [11,25]. Molecular modeling has somewhat clarified this issue. The steric fit of diaminoalkylphosphinic dipeptide possessing the additional β -amino group within the S1' subsite has to be virtually identical to that evidenced for the phosphinic analogue of hPhePhe, a potent inhibitor of *Nm*APN ($K_i = 302$ nM) [25]. Most probably the difference concerns the S1 region. Superimposition of two enzyme-inhibitor structures containing either *N'*-benzyl-1,2-diaminoalkylphosphonic acids (Fig. 2B) or the phosphinic analogue hPhePhe revealed that the P1 benzyl fragments of the two compounds adopt quite comparable conformations (Fig. 5). However, for **1n**, an intramolecular interaction P-O $\cdots$ HN that has been proposed for the amino acids is not allowed in the case of the dipeptide – the phosphonic oxygen involved in the bonding is replaced with a methylene linking the P1' portion. Typically, this oxygen atom is not involved in any specific contact, but in our case, its removal visibly alters the profitability. In general, this discussion adequately illustrates the subtlety of the design and development of bioactive ligands at the molecular level. Despite the rational approaches, the actual behavior of the molecules is governed by nuances that are difficult to predict.

Figure 5. Superimposition of *N'*-benzyl-1,2-diaminoalkylphosphonic acid (**1n**) structure with phosphinic hPhePhe analogue complexed with *NmAPN* ([25], PDB code 4QME). Intermolecular hydrogen bonds and ligand-metal interactions are marked in green.

Acknowledgments

The work was financed by a statutory activity subsidy from the Polish Ministry of Science and Higher Education for the Faculty of Chemistry of Wrocław University of Technology.

Ewelina Węglarz-Tomczak was supported by a grant from the Polish National Science Centre (Grant UMO-2012/05/N/ST5/01145). The Biovia Discovery Studio package was used under a Polish country-wide license. The use of software resources (Biovia Discovery Studio program package) of the Wrocław Centre for Networking and Supercomputing is also kindly acknowledged. The Structural Biology Center beamlines at APS are supported by the U.S. Department of Energy Office of Biological and Environmental Research program under Contract DE-AC02-06CH11357. The structural studies were performed at the Midwest Center for Structural Genomics supported by the National Institutes of Health Grant GM094585. We gratefully acknowledge Dr. M. Soroka for samples of N'-substituted diaminoethylphosphonic acids from MSJZ87 collection (compounds **1a**, **1b**, **1e**, **1f**, **1o**, **1v** and **1w**).

References

- [1] E. Węglarz-Tomczak, M. Poręba, A. Byzia, Ł. Berlicki, B. Nocek, Mulligan, A. Joachimiak, M. Drąg, A. Mucha, An integrated approach to the ligand binding specificity of *Neisseria meningitidis* M1 alanine aminopeptidase by fluorogenic substrate profiling, inhibitory studies and molecular modeling. *Biochimie*, **2013**, 95, 419-428.
- [2] S. E. Mace, Acute bacterial meningitis. *Emerg. Med. Clin. North Am.* **2008**, 26, 281-317.
- [3] L. H. Harrison, C. L. Trotter, M. E. Ramsey, Global epidemiology of meningococcal disease. *Vaccine* **2009**, 275, B51-B63.
- [4] J. Leimkugel, V. Racloz, L. Jacintho da Silva, G. Pluschke, Global review of meningococcal disease. A shifting etiology. *J. Bacteriol. Res.* **2009**, 1, 6-18.
- [5] M. Drąg, M. Bogyo, J. A. Ellman, G. S. Salvesen, Aminopeptidase fingerprints. An integrated approach for identification of good substrates and optimal inhibitors. *J. Biol. Chem.* **2010**, 285, 3310-3318.
- [6] M. Poręba, S. McGowan, T. S. Skinner-Adams, K. R. Trenholme, D. L. Gardiner, J. C. Whisstock, J. To, G. S. Salvesen, J. P. Dalton, M. Drąg, Fingerprinting the Substrate Specificity of M1 and M17 Aminopeptidases of Human Malaria, *Plasmodium Falciparum*. *PLoS One* **2012**, 7, e31938.
- [7] S. Gras, A. Byzia, F.B. Gilbert, S. McGowan, M. Drąg, A. Silvestre, A. Niepceron, F. Lecaille, G. Lalmanach, F. Brossier, Aminopeptidase N1 (EtAPN1), an M1 metalloprotease of the apicomplexan parasite *Eimeria tenella*, participates in parasite development. *Eukaryotic Cell* **2014**, 13, 884-895.

- [8] P. Mina-Osorio, The moonlighting enzyme CD13: Old and new functions to target. *Trends Mol. Med.* **2008**, *14*, 361-371.
- [9] M. Wickström, R. Larsson, P. Nygren, J. Gullbo, Aminopeptidase N (CD13) as a target for cancer chemotherapy. *Cancer Sci.* **2011**, *102*, 501-508.
- [10] T. S. Skinner-Adams, C. M. Stack, K. R. Trenholme, C. L. Brown, J. Grembecka, J. Lowther, A. Mucha, M. Drąg, P. Kafarski, S. McGowan, J. C. Whisstock, D. L. Gardiner, J. P. Dalton, *Plasmodium falciparum* neutral nminopeptidases: New targets for anti-malarials. *Trends Biochem. Sci.* **2010**, *35*, 53-61.
- [11] A. Mucha, P. Kafarski, L. Berlicki, Remarkable potential of the α -aminophosphonate/phosphinate structural motif in medicinal chemistry. *J. Med. Chem.* **2011**, *54*, 5955-5980.
- [12] B. Lejczak, P. Kafarski, J. Zygmunt, Inhibition of aminopeptidases by aminophosphonates. *Biochemistry* **1989**, *28*, 3549-3555.
- [13] A. Mucha, M. Drag, J. P. Dalton, P. Kafarski, Metalloaminopeptidase inhibitors. *Biochimie* **2010**, *92*, 1509-1529.
- [14] S. Rengaraju, K. D. Berlin, Slow nitrogen inversion due to intramolecular hydrogen bonding. Slow nitrogen inversion in diethyl 2-aziridinyolphosphonate from the paramagnetic-induced shifts in the PMR spectra using tris(dipivalomethanato)europium (III), and solvent shifts. *J. Org. Chem.* **1972**, *37*, 3304-3310.
- [15] J. Zygmunt, Aziridine-2-phosphonic acid, the valuable synthon for synthesis of 1-amino-2-functionalized ethanephosphonic acids. *Tetrahedron* **1985**, *41*, 4979-4982.
- [16] J. Zygmunt, P. Mastalerz, Synthesis of 1-amino-2-hydroxyethanephosphonic acid, the phosphonic analog of serine. *Pol. J. Chem.* **1981**, *55*, 411-414.
- [17] T. Ando, D. Kano, S. Minakata, I. Ryu, M. Komatsu, Iodine-catalyzed aziridination of alkenes using Chloramine-T as a nitrogen source. *Tetrahedron* **1998**, *54*, 13485-13494.
- [18] V. V. Thakur, A. Sudalai, N-Bromoamides as versatile catalysts for aziridination of olefins using Chloramine-T. *Tetrahedron Letters* **2003**, *44*, 989-992.
- [19] S. L. Jain, V. B. Sharma, B. Sain, An efficient transition metal-free aziridination of alkenes with Chloramine-T using aqueous H₂O₂/HBr. *Tetrahedron Letters* **2004**, *45*, 8731-8732.
- [20] D. Y. Kim, D. Y. Rhie, Synthesis of α -aminoalkylphosphonates from vinylphosphonates via aziridinyolphosphonates. *Tetrahedron* **1997**, *53*, 13603-13608.
- [21] S. Inoue, T. Okauchi, T. Minami, New synthesis of gem-bis(phosphono)ethylenes and their applications. *Synthesis* **2003**, 1971-1976.

- [22] Y. Liu, C. M. Che, [Fe(III)(F(20)-tpp)Cl] is an effective catalyst for nitrene transfer reactions and amination of saturated hydrocarbons with sulfonyl and aryl azides as nitrogen source under thermal and microwave-assisted conditions. *Chemistry* **2010**, *16*, 10494-10501.
- [23] O. Doğan, H. Babiz, G. Gözen, S. Budak, Synthesis of 2-aziridinyl phosphonates by modified Gabriel-Cromwell reaction and their antibacterial activities. *Eur. J. Med. Chem.* **2011**, *46*, 2485-2489.
- [24] B. Nocek, R. Mulligan, M. Bargassa, F. Collart, A. Joachimiak, Crystal structure of aminopeptidase N from human pathogen *Neisseria meningitidis*. *Proteins* **2008**, *70*, 273-279.
- [25] S. Vassiliou, E. Węglarz-Tomczak, Ł. Berlicki, M. Pawełczak, B. Nocek, R. Mulligan, A. Joachimiak, A. Mucha, Structure-guided, single-point modifications in the phosphinic dipeptide structure yield highly potent and selective inhibitors of neutral aminopeptidases. *J. Med. Chem.* **2014**, *57*, 8140-8151.
- [26] A. H. M. Wong, D. Zhou, J. M Rini, The X-ray crystal structure of human aminopeptidase N reveals a novel dimer and the basis for peptide processing. *J. Biol. Chem.* **2012**, *287*, 36804-36813.
- [27] J. Grembecka, A. Mucha, T. Cierpicki, P. Kafarski, The most potent organophosphorus inhibitors of leucine aminopeptidase. Structure-based design, chemistry, and activity. *J. Med. Chem.* **2003**, *46*, 2641-2655.
- [28] H. Stetter, H. Kuhlmann, Eine einfache Herstellung von α -Alkylacrylsäure-estern. *Synthesis* **1979**, 29-30.
- [29] S. Vassiliou, A. Mucha, P. Cuniasse, D. Georgiadis, K. Lucet-Levannier, F. Beau, R. Kannan, G. Murphy, V. Knäuper, M.-C. Rio, P. Basset, A. Yiotakis, V. Dive, Phosphinic pseudo-tripeptides as potent inhibitors of matrix metalloproteinases: a structure-activity study. *J. Med. Chem.* **1999**, *42*, 2610-2620.
- [30] H.-J. Cristau, A. Coulombeau, A. Genevois-Borella, F. Sanchez, J.-L. Pirat, Preparation of phosphinodipeptide analogs as building blocks for pseudopeptides synthesis *J. Organomet. Chem.* **2002**, *643/644*, 381-391.
- [31] M. Hoffmann, An efficient synthesis of dibenzyl and di-*p*-nitrobenzyl N-protected 1-aminoalkanephosphonates using isoureas. *J. Prakt. Chem.* **1988**, *330*, 820-824.
- [32] A. Mucha, P. Kafarski, F. Plenat, H.-J. Cristau, The preparation of phosphono peptides containing a phosphoramidate bond. *Tetrahedron* **1994**, *50*, 12743-12754.
- [33] K. S. Dunne, F. Bisaro, B. Odell, J.-M. Paris, V. Gouverneur, Diastereoselective ring-closing metathesis: synthesis of P-stereogenic phosphinates from prochiral phosphinic acid derivatives. *J. Org. Chem.* **2005**, *70*, 10803-10809.

- [34] A. Mucha, M. Drąg, J. P. Dalton, P. Kafarski, Metallo-aminopeptidase inhibitors. *Biochimie* **2010**, *92*, 1509-1529.
- [35] H. Chen, F. Noble, A. Mothé, H. Meudal, P. Coric, S. Danascimento, B. P. Roques, P. George, M.-C. Fournié-Zaluski, *J. Med. Chem.* **2000**, *43*, 1398-1408.
- [36] Turner, A. J. Aminopeptidase N. In Handbook of Proteolytic Enzymes, 3rd ed.; Rawlings, N. D., Salvesen, G., Eds.; Academic Press: Amsterdam, 2013; pp 397-403.
- [37] N. Sträter, W. N. Lipscomb, Leucyl Aminopeptidase (Animal). In Handbook of Proteolytic Enzymes, 3rd ed.; N. D. Rawlings, G. Salvesen, Eds.; Academic Press: Amsterdam, 2013; pp 1465-1470.
- [38] M. Drąg, J. Grembecka, M. Pawełczak, P. Kafarski, α -Aminoalkylphosphonates as a tool in experimental optimisation of P1 side chain shape of potential inhibitors in S1 pocket of leucine- and neutral aminopeptidases. *Eur. J. Med. Chem.* **2005**, *40*, 8, 764-771.
- [39] R. Gumpena, C. Kishor, R. J. Ganji, A. Addlagatta, Discovery of α,β - and α,γ -diamino acid scaffolds for the inhibition of M1 family aminopeptidases. *ChemMedChem*. **2011**, *6*, 1971-1976.
- [40] N. Sträter, W. N. Lipscomb, Transition state analogue L-leucinephosphonic acid bound to bovine lens leucine aminopeptidase: X-ray structure at 1.65 Å resolution in a new crystal form. *Biochemistry* **1995**, *34*, 9200-9210.